Follow Covalon Technologies Ltd. [TSX-V: COV] on :
Alyssa Hrycyshyn, VP of Marketing
Increased incidence of antibiotic resistance has heightened the awareness of the growing need to advance healthy healing through novel and innovative solutions in infection prevention. Having spotted this need, a group of entrepreneurial PhDs from the University of Toronto, Ontario, Canada, endeavoured to address these issues, and as a result, Covalon Technologies Ltd. [TSXV: COV] was established.
The Ontario-based medical devices manufacturer researches, develops, and commercializes healthcare innovations to manage and prevent infections related (but not limited) to advanced and chronic wounds, vascular access, and the perioperative space. Covalon Technologies’ product breadth currently spans a range of innovative healing and preventive devices including self-adherent silicones with antimicrobial agents, alginates, hydrocolloids, and new and novel advanced collagen biomatrix dressings. Alongside these commercialized products, Covalon Technologies, through its OEM segment, partners with many small, medium, and large medical device organizations to either co-create novel technologies, or support the development and commercialization of new products in various geographic markets and therapeutic areas. By working with these organizations, Covalon enables the advancement of products by incorporating active pharmaceutical ingredients (APIs) into its proprietary surface modification and coating capabilities. Alyssa Hrycyshyn, VP of Marketing at Covalon, says, “Through both our product and service segments, we aim to be the primary solutions provider to support infection prevention management in wound healing and medical device technology development.”
The organization’s novel perioperative line provides protection throughout the patient’s entire surgical journey. Beginning with MediClear® PreOp, a transparent, dual antimicrobial self-adherent silicone dressing applied after admission and worn into the OR to post surgical site protection with SurgiClearTM, an antimicrobial transparent protection and wound site monitoring, and post surgical scar management with MediClear™ Scar for managing the prevention of keloid and hyertrophic scars.
The breadth and depth of their advanced wound care portfolio showcases the organizations commitment to commercializing solutions for innovative healing.
Covalon’s product breadth and OEM service offerings currently span a range of healing, barrier protection and antimicrobial collagens, alginates, hydrocolloids, advanced biomatrix, and transparent silicone dressings, in addition to surface modification and coating capabilities
It’s ColActive® Plus, and ColActive® Plus Ag combine multiple mechanisms of action, (typically achieved with 4-5 different products), to accelerate wound repair in a single dressing alone, a prime example of how Covalon’s scientists develop formulations to improve capacity for healing.
In the case of their OEM segment, “Our experienced team, which comprises cross-disciplinary scientists and PhDs, work closely with each client to develop customized medical devices that provide superior performance (and durability) through our world-class surface modification and coating capabilities,” informs Alyssa. These competencies have enabled Covalon Technologies to position itself to address gaps or deficiencies in workflow or existing technologies which pose opportunity for infection. An example of this is the firm’s application of its proprietary, low particulate medical coating for interventional medical devices. Covalon Technologies first commercial device, the SilverCoat® Silicone Foley catheter, incorporated CovaCoat® Technology which provided clinicians an FDA-approved, device with an innovative and proprietary, antimicrobial coating to help reduce catheter related urinary tract infections.
“Whether it is a patient with compromised skin integrity, an aged diabetic patient with a complex chronic wound, or a med device company seeking assistance on surface modification or the incorporation of APIs, we have the know-how to develop technologies to promote infection prevention and advance patient health and quality of care,” states Alyssa.
The key to Covalon’s steady success lies in its ability to thoroughly understand the needs of the patient and its customers, to deliver products of the highest quality. This proficiency has garnered the firm a global presence across the Americas, APAC, and EMEA regions. Going forward, the company will continue to develop additional technologies and formulations that reduce infection and improve patient outcomes. With healthcare professionals increasingly seeking ways to accelerate healing and improve the quality of care, Covalon Technologies sits at a unique intersection, bringing a transformational change in the way infection prevention is managed.
Description A medical device manufacturer that combines science and technology to innovate healthcare medical devices by developing and commercializing medical technologies using proprietary design and development methodologies to advance treatment of advanced and chronic wounds, and promote infection prevention strategies across the healthcare continuum. Covalon Technologies was founded in 2004 by a group of with entrepreneurial PhDs from the University of Toronto, who recognized the opportunity to apply scientific method to innovate patented and advance healing alternatives in the global wound market. At its core, the Covalon team is comprised of cross-functional members who work closely to develop medical technologies using its proprietary antimicrobial formulations and/or its pioneering design and development approach to surface modification and coating to support infection prevention, and healthy healing strategies to improve the quality (and value) of care
This content is copyright protected
However, if you would like to share the information in this article, you may use the link below: